Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?

Current Opinion in Cardiology

Volumn 22, Issue 4, 2007, Pages 373-378

  Schaefer, Ernst J ^a   Asztalos, Bela F ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Cholesteryl ester transfer protein inhibition; Coronary heart disease; High density lipoprotein; Metabolism; Subpopulations

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; ROSUVASTATIN; TORCETRAPIB;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL TRANSPORT; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; RISK REDUCTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HEART DISEASES; HUMANS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 34250159840     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3281fbd3c7     Document Type: Review

References (38)

1. Schaefer EJ, Heaton WH, Wetzel MG, Brewer HB Jr. Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis 1982; 2:16-26.
2. Serfaty-Lacrosniere C, Lanzberg A, Civeira F, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107:85-98.
3. Asztalos BF, Brousseau ME, McNamara JR, et al. Subpopulations of high-density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 2001; 156:217-225.
4. Genest JJ, Martin-Munley S, McNamara JR, et al. Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025-2033.
5. Genest JJ Jr, Bard JM, Fruchart JC, et al. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 1993; 13:1728-1737.
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid lowering therapy on progression of coronary atherosclerosis in patients with acute coronary syndrome. JAMA 2004; 291:1071-1080.
7. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndrome: a randomized controlled trial. JAMA 2003; 290:2292-2300.
8. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA 2006; 295:1556-1565.
9. Tardif JC, Gregoire J, L'allier PL, et al. Effects of reconstituted high-density-lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675-1682.
10. Inazu A, Brown ML, Hesler CB, et al. Increased high density lipoprotein levels caused by a common cholesteryl-transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
11. Morehouse LA, Sugarman ED, Bourassa PA, et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet induced atherosclerosis in NZW rabbits. J Lipid Res 2007 [Epub ahead of print].
12. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose response study. Circulation 2002; 105:2159-2165.
13. Clark RW, Surfin TA, Ruggeri RB, et al. Raising high-density lipoproteins in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24:490-497.
14. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.
15. Hirano K, Yameshita S, Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr Opin Lipidol 2000; 11:589-596.
16. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101:1907-1912.
17. Asztalos BF, De la Llera-Moya M, Dallal GE, et al. Differential effects of HDL subpopulations on cellular ABCA1 and SRB1-mediated cholesterol efflux. J Lipid Res 2005; 46:2246-2253.
18. Asztalos BF, Horvath KV, Kajinami K, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004; 45:448-545.
19. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk. The Framingham Study. Arterioscler Thromb Vasc Biol 2000; 20:1323-1329.
20. Brousseau ME, O'Connor JJ, Ordovas JM, et al. Cholesteryl ester Transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease endpoints in men with HDL deficiency. Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002; 22:1148-1154.
21. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290:2030-2040.
22. Asztalos BF, Schaefer EJ, Horvath KV, et al. Role of LCAT in HDL remodeling: an investigation in LCAT deficiency states. J Lipid Res 2007; 48:592-599. Study investigating the role of lecithin:cholesterol acyl transferase on HDL remodeling. The data indicate that lack of lecithin:cholesterol acyl transferase results in the inability to form spherical HDL particles containing both apoA-I and A-II, and the accumulation of α-4 HDL that is discoidal, small and contains apoA-I without A-II. No major effect on apoE HDL was noted, except that here again the particles are likely to be discoidal rather than spherical due to the inability to esterify cholesterol and form cholesteryl ester in the core of HDL.
23. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24:2181-2187.
24. Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005; 25:2185-2191.
25. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:847-852.
26. Asztalos BF, LeMaulf F, Dallal GE, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on subpopulations of high density lipoproteins. Am J Cardiol 2007; 99:681-685. This study examined the effects of rosuvastatin 40 mg/day vs. atorvastatin 8 mg/day in the STELLAR study. The data indicates that both statins lower preβ-1 HDL by about 40%, suggesting more efficient reverse cholesterol transport, but that rosuvastatin is about twice as effective at raising large α-1 HDL than atorvastatin, possibly because of its longer plasma residence time and greater efficacy. Greater increases in this HDL fraction have been linked to greater benefit in promoting regression of coronary atherosclerosis. These data may explain why rosuvastatin at 40 mg/day promoted median regression of coronary atheroma volume while atorvastatin 80 mg/day promoted lack of progression.
27. Clark RW, Ruggieri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester protein inhibitors, including mechanism of action. J Lipid Res 2006; 47:537-552. An important study which documented that torcetrapib and other Pfizer CETP inhibitors bind to CETP on the HDL particle. This binding process forms a nonproductive complex which may interfere with the functions of HDL, which include reverse cholesterol transport, prevention of inflammation and prevention of lipid oxidation.
28. Qui X, Mistry A, Ammirati MJ, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four lipid bound molecules. Nat Struct Mol Biol 2007; 14:106-113. Documentation of the crystal structure of CETP revealing a long tunnel and four lipid-bound molecules. This tunnel allows for the transfer of cholesteryl ester and triglyceride between HDL and triglyceride-rich lipoproteins in a hydrophobic manner in the plasma space. Understanding the crystal structure of CETP should allow scientists to design optimal CETP inhibitors that do not bind to HDL or interfere with any of its functions.
29. Dumont L, Gauthier T, De Barros JP, et al. Molecular mechanism of the blockade of plasma cholesteryl ester protein by its physiologic inhibitor apolipoprotein CI. J Biol Chem 2005; 280:38108-38116.
30. Cheema SK, Agarwal-Mawal A, Murray CM, Tucker S. Lack of stimulation of cholesteryl ester transfer protein by cholesterol in the presence of a high fat diet. J Lipid Res 2005; 46:2356-2366.
31. Kee P, Cantazza D, Rye KA, et al. Effect of inhibiting cholesteryl ester protein on the kinetics of high-density lipoprotein cholesteryl ester transport in plasma. In vivo studies in rabbits. Arterioscler Vasc Thromb Biol 2006; 26:884-890.
32. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 2005; 25:1057-1064.
33. Millar JS, Brousseau ME, Diffenderfer MR, et al. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism. Arterioscler Thromb Vasc Biol 2006; 26:1350-1356.
34. Lloyd DB, Lira ME, Woods LS, et al. Cholesteryl ester protein variants have differential stability but uniform inhibition by torcetrapib. J Biol Chem 2005; 280:14918-14922.
35. Kuivenhoven JA, De Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005; 95:1085-1088.
36. Pfizer. In the interests of patient safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities [news release]. New York: Pfizer 2006; http://mediaroom.pfizer.com/index.php?s= press_release&item=130.
37. Nissen SE, Tardif JC, Nicholls SJ, et al. Effects of torcetrapib on progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316. In a study of 910 evaluable patients with coronary atherosclerosis who underwent IVUS at baseline and at 24 months, no significant benefit of the torcetrapib-atorvastatin combination was noted vs. atorvastatin alone on the primary endpoint which was percentage change in total atheroma volume, despite marked increases in HDL-cholesterol.
38. Kastelein JJ, Van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620-1630. In a study of 850 patients with familial hypercholesterolemia treated with atorvastatin plus placebo or atorvastatin plus torcetrapib over 2 years carotid intimal medial thickness was assessed by ultrasound. No significant differences in treatment groups were observed for the primary endpoint (maximal carotid intima media thickness) between groups despite dramatic differences in HDL-cholesterol level.